VBI Vaccines up after VBI-1901 data in early-stage brain cancer study

 

• VBI Vaccines (NASDAQ:VBIV) rises 4% in premarket, after announcing data from Phase 2a (Part B) from its ongoing Phase 1/2a study evaluating its cancer vaccine candidate, VBI-1901, designed to target cytomegalovirus (CMV) as a foreign viral antigen in recurrent glioblastoma (GBM), an aggressive form of cancer that occurs in brain or spinal cord.
• Interim data showed 2 partial responses and 2 stable disease in the VBI-1901 + GM-CSF vaccinated group, resulting in a disease control rate of 40% (n=4/10).
• 56% disease control rate achieved in the group vaccinated with VBI-1901 combined with GSK’s adjuvant AS01, with 5 stable disease observations (n=5/9);tumor response data for the 10th patient enrolled is pending.
• Presumed pseudoprogression was observed in both vaccinated groups– defined as immune infiltration into the tumor which appears initially as tumor growth, but later subsides resulting in tumor growth stabilization and/or shrinkage.
• On the safety front, VBI-1901 was well-tolerated with both adjuvants, and no safety signals observed in either vaccinated group.
• VBI is exploring a potential registration study, for the next phase of development, which could begin in 2021.
• https://seekingalpha.com/news/3637918-vbi-vaccinesplus-4-after-vbiminus-1901-data-in-early-stage-brain-cancer-study